A phase Ib clinical trial on the preliminary efficacy, safety, and pharmacokinetics of oral sialic acid to sensitize combined immunotherapy and targeted therapy in patients with unresectable advanced hepatocellular carcinoma

Start Date22 Sep 2025

Sponsor / Collaborator

Zhongshan Hospital Fudan University

NCT04671472

/ CompletedPhase 3

Efficacy Confirmation Study of NPC-09

GNE myopathy is a distal myopathy that is thought to be caused by a mutation in the GNE gene that encodes an enzyme in the biosynthetic process of aceneuramic acid (typical sialic acid). The investigators will examine the efficacy and safety of aceneuramic acid (SA-ER tablets) 6g daily for 48 weeks in patients with GNE myopathy in a placebo-controlled, double-blind, controlled trial.

Start Date08 Feb 2021

Sponsor / Collaborator

Nobelpharma Co., Ltd.

NCT03775967

/ CompletedNot ApplicableIIT

Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients

Sialic acid (SA) is the generic term given to a family of acetylated derivatives of neuraminic acid. SA is a 9 carbon monosaccharide. An important function of host SA is to regulate innate immunity. SA is present in several acute phase proteins which are known to be associated with periodontitis. There exists a need for a biomarker, for early detection of disease evolution and more robust therapy efficacy measurements. Till date, there is very little data regarding simultaneous estimation and comparison of total SA content in saliva. IL-10, an anti-inflammatory cytokine, regulates the synthesis of pro-inflammatory cytokines such as IL-1, -2, -6 and stimulates protective antibody production. IL-10 is expressed in both healthy and diseased human periodontal tissues and is reported to be reduced in patients infected with Aggregatibacter actinomycetemcomitans.
The present study was therefore undertaken with an aim, to not only assess the levels of TSA(Total sialic acid levels),but also of IL 10 levels in saliva from stage 1(mild) to stage 2(moderate) periodontitis patients

Start Date10 Oct 2018

Sponsor / Collaborator

Ajman University

100 Clinical Results associated with Aceneuramic acid

100 Translational Medicine associated with Aceneuramic acid

100 Patents (Medical) associated with Aceneuramic acid

3,661

Literatures (Medical) associated with Aceneuramic acid

01 Feb 2026·JOURNAL OF NUTRITION

Sialic Acid Supplementation in Perinatal Mice Attenuates Gestational Diabetes Mellitus–Induced Liver Injury in Offspring at Early Adulthood

Article

Author: Hao, Huilei ; Wang, Ying ; Li, Lemei ; Wu, Jinyang ; Hou, Shaoying

BACKGROUND:

Gestational diabetes mellitus (GDM) is prone to induce hepatic injury in offspring. Sialic acid (SA) exhibits hepatoprotective effects, whereas its potential against GDM-induced liver injury in offspring remains unclear.

OBJECTIVES:

The present study aimed to investigate the hepatoprotective effects of maternal SA supplementation in GDM-exposed offspring and to explore its underlying mechanisms.

METHODS:

C57BL/6J mice were divided into 3 groups: a control (NC-m) group, a gestational diabetes mellitus (GDM-m) group, and a gestational diabetes mellitus plus SA (GDM+SA-m) group. The GDM-m group was induced using a high-fat diet combined with intraperitoneal streptozotocin injection. The GDM+SA-m group was administered N-glycolylneuraminic acid (Neu5Ac), human milk SA, via intragastric gavage at a dose of 50 mg/kg during pregnancy and lactation. Offspring from 3 groups were fed a control diet until 8 wk of age, with 20, 20, and 19 in the NC-o, GDM-o, and GDM+SA-o groups, respectively. Liver was obtained and analyzed for hematoxylin and eosin staining, aspartate aminotransferase and alanine aminotransferase, oxidative stress markers, inflammatory cytokines, and nontargeted metabolomics.

RESULTS:

Compared with the NC-o group, GDM significantly elevated liver transaminase levels and increased inflammatory and oxidative stress in offspring mice, with more pronounced effects observed in males. SA intervention partially attenuated this damage. Concurrently, metabolomic analysis revealed that SA significantly regulated lipid metabolism and taurine/hypotaurine pathways.

CONCLUSIONS:

The results suggested that maternal SA intervention ameliorated GDM-induced offspring liver injury, potentially by regulating hepatic lipid and taurine/hypotaurine metabolism, providing a novel mechanistic insight for early-life intervention in GDM.

01 Feb 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Deletion of Glaesserella parasuis nanA promotes apoptosis by inhibiting PINK1/Parkin pathway

Article

Author: Huan, Shijiao ; Tan, Yuqing ; Lei, Zhixin ; Wu, Ziyue ; Liu, Yaqin

Glaesserella parasuis (G. parasuis) is the primary pathogen responsible for Glasser's disease in large-scale pig farms. It causes annual mortality rates of 10-20% in weaned piglets due to meningitis, serositis, and sudden death syndrome. The rapid spread of multidrug-resistant strains has reduced the cure rate of macrolide antibiotics and other drugs, resulting in significant economic losses in the livestock industry. Based on a previously established Tildipirosin-resistant G. parasuis strain (Wang et al., 2025), this study confirmed that nanA is a virulence gene. To investigate its function, we constructed a ΔnanA deletion mutant. The results demonstrated that nanA deletion markedly reduced G. parasuis adhesion to PK-15 cells, cellular toxicity, and minimum inhibitory concentration (MIC), suggesting that this gene plays a crucial role in bacterial pathogenicity and resistance. Further studies revealed that G. parasuis infection induced mitophagy in PK-15 cells, a process that was significantly inhibited by the ΔnanA mutant. By knocking down the Pink1 gene, we confirmed that the ΔnanA mutant strain attenuated G. parasuis-induced mitophagy via the PINK1/Parkin signaling pathway, a mechanism validated in mouse models. Furthermore, qPCR and flow cytometry results indicated that nanA deletion exacerbated G. parasuis-induced apoptosis. In summary, this study demonstrates that G. parasuis enhances its virulence by inducing mitophagy, whereas nanA deletion promotes apoptosis by inhibiting autophagy. These findings elucidate a key aspect of G. parasuis pathogenesis and highlight the central role of NanA in this process.

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development and validation of a label-free HPLC-CAD method to determine total sialic acid in therapeutic proteins

Article

Author: Xu, Yuechuan Alex ; Chen, Zhi ; Zeng, Ming ; Peddicord, Michael ; Cheng, Julie ; Peters, Björn-Hendrik ; Wang, Yifei ; Qiu, Difei

Sialylation plays a crucial role in influencing the pharmacokinetic, chemical, physical, and immunogenic properties of therapeutic proteins and is commonly tracked through total sialic acid analysis. In this study, we developed a novel label-free HPLC method to monitor total sialic acid levels in protein drug products. The method utilizes a replaceable, pre-column C18 cartridge that removes protein in-line, preventing protein interference with sialic acid and contamination of the analytical column and enabling direct sample injection. The optimized mixed-mode hydrophilic interaction-ion exchange liquid chromatography (HILIC-IEX) separation condition includes a volatile mobile phase for charged aerosol detection (CAD) of sialic acids. The method was validated to demonstrate satisfactory specificity, linearity (R > 0.999), precision (RSD between 0.4 % and 2.1 %), sensitivity (QL < 25 ng), and accuracy (recovery between 93 % and 102 %). It was successfully applied to determine total sialic acids in a model protein drug product, demonstrating promising potential as an accurate, robust, efficient, and cost-effective approach for sialylation evaluation.

News (Medical) associated with Aceneuramic acid

23 Mar 2017

·www.biospace.com

Bay Area’s Ultragenyx Tanks as Seizure Drug Flunks Phase II Test

March 23, 2017 By Alex Keown , BioSpace.com Breaking News Staff NOVATO, Calif. – Shares of Ultragenyx Pharmaceuticals are down more than 8 percent today after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals. In its announcement, Ultragenyx said UX007 did not reduce the frequency of number of observable seizures among patients during an eight-week period of treatment. The company said treatment with UX007 did show a reduction in absence seizures captured on EEG, but not observable seizures captured by diary. Patients treated with UX007 demonstrated a reduction of 13.4 percent in overall seizure frequency relative to placebo, the company said in its announcement. During the Phase II trial, patients kept a daily seizure diary to capture observable seizures in patients. An electroencephalography (EEG) was used at baseline and week eight to capture absence seizures. Dosing was initiated over a two-week titration period until the patient reached the target dose of 35 percent of total daily calories from UX007, the company said. UX007 is a highly purified, pharmaceutical-grade synthetic seven carbon fatty acid triglyceride intended to provide patients with medium-length, odd-chain fatty acids that can be metabolized to increase intermediate substrates in the Krebs cycle, a key energy-generating process, according to company information. The drug is being developed to treat seizures in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS is a severely debilitating disease characterized by seizures, developmental delay, and movement disorders. Glut1 DS is caused by a genetic defect in the transport of glucose into the brain. There are currently no FDA approved treatments specific to Glut1 DS. Emil D. Kakkis , president and chief executive officer of Ultragenyx , said the Phase II data showing the 13.4 percent reduction in seizures suggests UX007 has a “clinically meaningful effect in Glut1DS patients with absence seizures.” Kakkis said the company is looking forward to continue studying UX007 in Ultragenyx’s Phase III study in Glut1 DS patients with movement disorders. He said the company will continue to evaluate its options for UX007 in the indication for seizures. There were no deaths and no treatment-related serious adverse events during the trial. Two of the 36 enrolled patients discontinued treatment during the eight-week placebo-controlled period. During the trial, 12 patients discontinued use during the extension period. Two patients discontinued due to adverse events, four patients due to tolerability reasons and eight for compliance or study burden issues, the company said. Ultragenyx could get a rebound if news is positive regarding its Phase III enzyme replacement therapy candidate rhGUS for the treatment of Mucopolysaccharidosis 7. In July, the company announced the late-stage study met its primary endpoint of reducing urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment. Ultragenyx is set to seek regulatory approval with the U.S. Food and Drug Administration and the European Medicines Agency later this year. In November, Ultragenyx was forced to shelve plans for a quick approval of its investigational Aceneuramic Acid Prolonged Release (Ace-ER) for the treatment of adult patients with GNE Myopathy. The company announced it withdrew a conditional Marketing Authorization Application after a Phase II study “did not provide a sufficient amount of evidence to support an approval” at the time it was received. The company has launched a Phase III trial and plans to submit another MAA to the EMA after data is available later this year.

Phase 2Phase 3Clinical Result

20 Jan 2017

·www.bioportfolio.com

Ultragenyx Pharmaceutical Inc RARE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

Summary Ultragenyx Pharmaceutical Inc Ultragenyx is a biotechnology company that develops lifeenhancing therapeutics for rare and ultrarare genetic diseases. The company's products include KRN23, rhPPCA, rhGUS, UX007 and Aceneuramic acid. Its Aceneuramic acid is developed for multiple rare genetic disorders. Ultragenyx develops recombinant fully human monoclonal IgG1 antibody, KRN23 to treat bone disease XLinked Hypophosphatemia and tumorinduced osteomalacia. The company also develops investigational enzyme replacement therapies, recombinant human betaglucuronidase for the development for Mucopolysaccharidosis 7 and rhPPCA for treatment of galactosialidosis. It partners with academic institutes and companies. Ultragenyx is headquartered in Novato, California, the US. Ultragenyx Pharmaceutical Inc RARE Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

AntibodyAcquisition

100 Deals associated with Aceneuramic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D11016	Aceneuramic acid	M09AX05	DB11797

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Distal Myopathy, Nonaka Type	Japan	Nobelpharma Co., Ltd.	26 Mar 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucopolysaccharidosis VII	Phase 3	United Kingdom	Ultragenyx Pharmaceutical, Inc.	04 Jul 2016
Thrombocytopenia	Phase 2	-	Hadassah University Hospital	01 Sep 2016
Acute Lung Injury	Preclinical	China	Central South University of Forestry & Technology	20 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04671472 (phase III, Pubmed \| Orphanet J Rare Dis)	Phase 3	Distal Myopathy, Nonaka Type mutations in the GNE gene	14	Aceneuramic acid (SA-ER)	xxudpkdzqu(hexgdjfvpv): LSM difference = 2.51	Positive	11 Aug 2023
				Placebo
NCT02377921 (UX001-CL301, Pubmed \| Ann Neurol \| Neurology) Manual	Phase 3	Distal Myopathy, Nonaka Type	89	aceneuramic acid	chkgcpgkwk(jbmqgoface) = utwuagorwc goqwwoguke (vonrxgoqlh )	Negative	30 Apr 2019
				Placebo	chkgcpgkwk(jbmqgoface) = cmmeclzxkj goqwwoguke (vonrxgoqlh )
NCT02731690 (CTgov)	Phase 2	Distal Myopathy, Nonaka Type	42	UX001 (UX001 6g/Day)	inzmureomt = kfgnegsaow jnvtzetsqx (gcykshwrbp, lwnfwfckce - yhccircmps) View more	-	19 Feb 2019
				Ace-ER (Ace-ER 6 g/Day)	lhhyvtssoz(iisegeafyi) = xydvutkxmj otaqayfxwr (cskcrbsmip, oxlrosyzlu - rmtczlyjrd) View more
NCT02736188 (CTgov)	Phase 3	Distal Myopathy, Nonaka Type	143	Ace-ER (Ace-ER 6 g/Day)	cbmpyfsfvg = xjpnbbyyvi cdbevqjnri (itvvlazcmz, lkddhjkomi - ujcfxozkpl) View more	-	19 Feb 2019
				Ace-ER (Ace-ER 6 g/Day (Parent Study Treatment: Ace-ER 6 g/Day))	pgjmrddsgn(vlhxkwvelb) = wgzavxwxue zztxubaqqw (cmmutohzjv, kyclpjbouo - outajjgacu) View more
NCT02377921 (UX001-CL301 \| GNEM, CTgov)	Phase 3	Distal Myopathy, Nonaka Type	89	Placebo	jyxqwmxjjl(fkeejoxqsr) = uudaikdgbl iipfhgmfxa (iloyhlxltc, xpubywhaoa - nkjvywxfzi) View more	-	09 Jul 2018
NCT01830972 (CTgov)	Phase 2	Distal Myopathy, Nonaka Type	59	SA-IR 500 mg (Crossover Participants)	shlrlppqfk = nvitnzgiyh jsrnhtjjvs (ezflqzkeww, wxtqukopkr - utbfpnnjjx) View more	-	13 Mar 2018
				SA-IR 500 mg (Naïve Participants)	gowpqdunwl = krblissisw vnrcaavcnx (nltouwarya, qskaedrywu - tzzdnleigj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis